Kazuo Ohtsuka

Kazuo Ohtsuka

Auto-generated profile, based on publicly available information

Kazuo Ohtsuka

Department of Endoscopy Institute of Science Tokyo Hospital Tokyo Japan

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in Journal of Gastroenterology
Verified
Journal Article
Open access
PDF file
MKMasahiro Kishi
Masahiro Kishi
FHFumihito Hirai
Fumihito Hirai
NTNoritaka Takatsu
Noritaka Takatsu
THTakashi Hisabe
Takashi Hisabe
YTYasumichi Takada
Yasumichi Takada
THTadakazu Hisamatsu
Tadakazu Hisamatsu
Many clinical trials have been conducted for inflammatory bowel disease (IBD), so various clinical indices (CIs) and endoscopic indices (EIs) have also been evaluated. However, recently, with the progress of IBD management, review of established indices from previous studies, and establishment of new indices, the landscape of the use of indices in clinical trials have changed. We investigated the number and frequency of the indices adapted in recent clinical trials for ulcerative colitis (CI and EI) and Crohn’s disease (CI, EI, index related to magnetic resonance imaging, index for evaluating patient-reported outcomes, and health-related quality of life). Based on the results, we selected representative indices and further reviewed their content and characteristics. Moreover, various definitions, including clinical and endoscopic response or remission, have been described by means of representative indices in clinical trials.

1 May 2021 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
KTKento Takenaka
Kento Takenaka
KOKazuo Ohtsuka
Kazuo Ohtsuka
TFToshimitsu Fujii
Toshimitsu Fujii
SOShiori Oshima
Shiori Oshima
RORyuichi Okamoto
Ryuichi Okamoto
MWMamoru Watanabe
Mamoru Watanabe

1 June 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
KTKento Takenaka
Kento Takenaka
TFToshimitsu Fujii
Toshimitsu Fujii
KSKohei Suzuki
Kohei Suzuki
HSHiromichi Shimizu
Hiromichi Shimizu
MMMaiko Motobayashi
Maiko Motobayashi
KOKazuo Ohtsuka
Kazuo Ohtsuka

29 July 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
KTKento Takenaka
Kento Takenaka
AKAmi Kawamoto
Ami Kawamoto
SHShuji Hibiya
Shuji Hibiya
KSKohei Suzuki
Kohei Suzuki
TFToshimitsu Fujii
Toshimitsu Fujii
KOKazuo Ohtsuka
Kazuo Ohtsuka

30 April 2022 in Intestinal Research
Verified
Journal Article
Open access
PDF file
KTKento Takenaka
Kento Takenaka
AKAmi Kawamoto
Ami Kawamoto
RORyuichi Okamoto
Ryuichi Okamoto
MWMamoru Watanabe
Mamoru Watanabe
KOKazuo Ohtsuka
Kazuo Ohtsuka
Inflammatory bowel disease (IBD), with its 2 subtypes, Crohn’s disease and ulcerative colitis, is a complex chronic condition. A precise definition of disease activity and appropriate drug management greatly improve the clinical course while minimizing the risk or cost. Artificial intelligence (AI) has been used in several medical diseases or situations. Herein, we provide an overview of AI for endoscopy in IBD. We discuss how AI can improve clinical practice and how some components have already begun to shape our knowledge. There may be a time when we can use AI in clinical practice. As AI systems contribute to the exact diagnosis and treatment of human disease, we should continue to learn best practices in health care in the field of IBD.

30 January 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
HSHiromichi Shimizu
Hiromichi Shimizu
TFToshimitsu Fujii
Toshimitsu Fujii
SHShuji Hibiya
Shuji Hibiya
MMMaiko Motobayashi
Maiko Motobayashi
KSKohei Suzuki
Kohei Suzuki
MWMamoru Watanabe
Mamoru Watanabe